E-LIB Suche - Ergebnisse für: Jaksa, A

1

HTA3 Analysis of Canadian and International Health Technolo..:

Arena, P. ; Jaksa, A. ; A, Brière.
Value in Health. 26 (2023) 6 - p. S259 , 2023

Link: https://doi.org/10.1016/..

2

EE155 The Impact of Value-Based Pricing (VBP) Vs Internatio..:

Labban, M ; Patrick, A ; Mahendraratnam Lederer, N...
Value in Health. 25 (2022) 7 - p. S364 , 2022

Link: https://doi.org/10.1016/..

3

RWD84 The Role of Real-World Evidence in Cell and Gene Ther..:

Honig, N ; Arena, P ; Mahendraratnam Lederer, N.
Value in Health. 25 (2022) 12 - p. S465 , 2022

Link: https://doi.org/10.1016/..

4

PNS174 COMMON THREADS: REGULATORY AND HEALTH TECHNOLOGY ASS..:

Jaksa, A. ; Gatto, N. ; Case, A.
Value in Health. 23 (2020) - p. S315-S316 , 2020

Link: https://doi.org/10.1016/..

5

PRO106 IMPACT of De Novo Real-World Evidence (RWE) Generati..:

Jaksa, A. ; Bradt, P. ; Patrick, A...
Value in Health. 23 (2020) - p. S708 , 2020

Link: https://doi.org/10.1016/..

6

ON3 Comparison of External Control Arm (ECA) Critiques in R..:

Jaksa, A. ; Vondeling, G. ; Martin, L....
Value in Health. 23 (2020) - p. S408 , 2020

Link: https://doi.org/10.1016/..

7

PDG74 AVAILABILITY OF FDA-APPROVED SURROGATE MARKERS IN REA..:

Weckstein, A. ; Rubinstein, E. ; Patrick, A..
Value in Health. 23 (2020) - p. S142 , 2020

Link: https://doi.org/10.1016/..

8

PIN76 CHARACTERISTICS OF PATIENTS WITH CHRONIC HEPATITIS C ..:

Patrick, A. ; Tsukernik, M. ; Jaksa, A.
Value in Health. 23 (2020) - p. S181 , 2020

Link: https://doi.org/10.1016/..

9

RE2 THEMES IN THE DESIGN OF PHARMACEUTICAL VALUE-BASED CONT..:

Adimadhyam, S. ; Weckstein, A. ; Patrick, A...
Value in Health. 22 (2019) - p. S920-S921 , 2019

Link: https://doi.org/10.1016/..

10

PDG87 ARE VALUE ASSESSMENT FRAMEWORKS USING RWE? A REVIEW O..:

Jaksa, A. ; Skornicki, M. ; Patrick, A.
Value in Health. 22 (2019) - p. S611 , 2019

Link: https://doi.org/10.1016/..

11

Health Techonolgy Assessment (HTA) Agencies Consideration o..:

Jao, R ; Jaksa, A ; Pontynen, A.
Value in Health. 21 (2018) - p. S7 , 2018

Link: https://doi.org/10.1016/..

12

Does The Traditional Hta Process Appropriately Evaluate Bra..:

Adler, B ; Versoza, L ; Jaksa, A...
Value in Health. 21 (2018) - p. S47 , 2018

Link: https://doi.org/10.1016/..

13

Different Values In Cost-Effectiveness Research: Institute ..:

Liden, D ; Jaksa, A
Value in Health. 19 (2016) 7 - p. A501 , 2016

Link: https://doi.org/10.1016/..

14

Key Drivers of HTA Decisions for "Life-Changing" Drugs:

Jaksa, A ; Peress, E ; Viana, R
Value in Health. 19 (2016) 7 - p. A491 , 2016

Link: https://doi.org/10.1016/..

15

Institute for Clinical and Economic Review (ICER) VS. Healt..:

Jaksa, A ; Liden, D
Value in Health. 19 (2016) 7 - p. A494 , 2016

Link: https://doi.org/10.1016/..